# ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct05650879/  
OnCo record `nct05650879` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of ELVN-002 run by Enliven Therapeutics, active and no longer recruiting.

## Summary

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer is a phase 1 interventional study registered as NCT05650879 by Enliven Therapeutics, with 198 participants planned, started 2023-03-20. Conditions recorded: HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation and HER2 Amplification. Interventions recorded: ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki and Trastuzumab emtansine.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05650879
- Phase: 1
- Setting: A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer
- Sponsor: Enliven Therapeutics
- Enrolled: 198

## Sources

- ClinicalTrials.gov NCT05650879: https://clinicaltrials.gov/study/NCT05650879

## Connected records

- cancers: [HER2-mutant non-small-cell lung cancer](https://onco.cc/cancers/her2-mutant-nsclc/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [ELVN-002](https://onco.cc/drugs/elvn-002/)
- companies: [Enliven Therapeutics](https://onco.cc/companies/enliven-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05650879.json